Parkinson’s Study Probes Link to Ashkenazi Mutation
A study sponsored by The Michael J. Fox Foundation for Parkinson’s Research will investigate a genetic mutation found more often in Ashkenazi Jews.
The Parkinson’s Progression Markers Initiative, a large-scale biomarker study, is expanding to study individuals with genetic mutations associated with Parkinson’s disease.
Among those mutations is the LRRK2, which accounts for a greater number of Parkinson’s cases among certain ethnic populations and families, notably Jews of Eastern European descent.
The study will enroll 250 people with the LRRK2 mutation and Parkinson’s and a like number with the mutation but without Parkinson’s.
Genetic mutations account for 5 percent to 10 percent of all Parkinson’s cases, but a study of these individuals may reveal disease traits that apply to all Parkinson’s patients.
The Fox Foundation has secured 15 industry partners and co-funding sponsors for the initiative. They include Abbott Laboratories, Biogen, BMS, Covance, Eli Lilly, GE Healthcare, Genentech, GSK, Merck, Pfizer and Roche.
The study will take place at 32 clinical sites around the world.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
